Lexicon Pharma (LXRX) Tops Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.39 +6.70%
Revenue Growth %: -86.1%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
UBAB, LOAN, FITB, More
Revenue Growth %: -86.1%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $1.65 million versus the consensus estimate of $3.44 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
- Boxabl completes SPAC merger, begins trading on Nasdaq at $3.5B value
- Energy Vault Holdings (NRGV) files $300M mixed shelf
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
